Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Evolving approaches to patients with advanced differentiated thyroid cancer.

Haugen BR, Sherman SI.

Endocr Rev. 2013 Jun;34(3):439-55. doi: 10.1210/er.2012-1038. Epub 2013 Apr 10. Review. Erratum in: Endocr Rev. 2013 Dec;34(6):925.

2.

Lenvatinib: Role in thyroid cancer and other solid tumors.

Cabanillas ME, Habra MA.

Cancer Treat Rev. 2016 Jan;42:47-55. doi: 10.1016/j.ctrv.2015.11.003. Epub 2015 Dec 2. Review.

3.

Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Narayanan S, Colevas AD.

Curr Treat Options Oncol. 2016 Jun;17(6):30. doi: 10.1007/s11864-016-0404-6. Review.

PMID:
27139457
4.

The discovery and development of sorafenib for the treatment of thyroid cancer.

White PT, Cohen MS.

Expert Opin Drug Discov. 2015 Apr;10(4):427-39. doi: 10.1517/17460441.2015.1006194. Epub 2015 Feb 8. Review.

5.

Targeted Therapy in Thyroid Cancer: State of the Art.

Valerio L, Pieruzzi L, Giani C, Agate L, Bottici V, Lorusso L, Cappagli V, Puleo L, Matrone A, Viola D, Romei C, Ciampi R, Molinaro E, Elisei R.

Clin Oncol (R Coll Radiol). 2017 May;29(5):316-324. doi: 10.1016/j.clon.2017.02.009. Epub 2017 Mar 17. Review.

PMID:
28318881
6.

Neoadjuvant Therapy in Differentiated Thyroid Cancer.

Dang RP, McFarland D, Le VH, Camille N, Miles BA, Teng MS, Genden EM, Misiukiewicz KJ.

Int J Surg Oncol. 2016;2016:3743420. Epub 2016 Sep 22. Review.

7.

[Use of new molecules in the treatment of advanced thyroid cancer].

Galofré JC, Gómez-Sáez JM, Álvarez Escola C, Álvarez García E, Anda Apiñaniz E, Calleja A, Donnay S, Lucas-Martin A, Menéndez Torre E, Navarro González E, Pereg V, Pérez Corral B, Santamaría Sandi J, Riesco Eizaguirre G, Zafón Llopis C; Toma de posición del Grupo de Trabajo de Cáncer de Tiroides de la Sociedad Española de Endocrinología y Nutrición.

Endocrinol Nutr. 2011 Oct;58(8):381-6. doi: 10.1016/j.endonu.2011.07.001. Epub 2011 Sep 15. Review. Spanish. No abstract available.

PMID:
21924966
8.

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL.

J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95. doi: 10.1210/jc.2009-1923. Epub 2010 Apr 14.

PMID:
20392874
9.

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.

Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH.

J Clin Oncol. 2017 Oct 10;35(29):3315-3321. doi: 10.1200/JCO.2017.73.0226. Epub 2017 Aug 17.

PMID:
28817373
10.

Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.

Kawalec P, Malinowska-Lipień I, Brzostek T, Kózka M.

Expert Rev Anticancer Ther. 2016 Dec;16(12):1303-1309. Epub 2016 Oct 28. Review.

PMID:
27734713
11.

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.

Wang E, Karedan T, Perez CA.

Anticancer Drugs. 2015 Aug;26(7):689-97. doi: 10.1097/CAD.0000000000000247. Review.

PMID:
25974026
12.

Sequencing of Tyrosine Kinase Inhibitors in Progressive Differentiated Thyroid Cancer.

Brose MS.

Clin Adv Hematol Oncol. 2016 May;14(5 Suppl 9):7-12. Review. No abstract available.

PMID:
27168342
13.

An update on clinical trials of targeted therapies in thyroid cancer.

Haraldsdottir S, Shah MH.

Curr Opin Oncol. 2014 Jan;26(1):36-44. doi: 10.1097/CCO.0000000000000029. Review.

PMID:
24240178
14.

Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.

Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R.

J Clin Endocrinol Metab. 2011 Apr;96(4):997-1005. doi: 10.1210/jc.2010-1899. Epub 2011 Feb 2. Erratum in: J Clin Endocrinol Metab. 2012 Apr;97(4):1399. J Clin Endocrinol Metab. 2011 Jul;96(7):2286. Busaidy, Naifa L [added]; El Naggar, Alder K [corrected to El Naggar, Adel K].

15.

Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches.

Harris PJ, Bible KC.

Expert Opin Investig Drugs. 2011 Oct;20(10):1357-75. doi: 10.1517/13543784.2011.614230. Review.

16.

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA.

J Clin Invest. 2011 Dec;121(12):4700-11. doi: 10.1172/JCI46382. Epub 2011 Nov 21.

17.

Evolving approaches in managing radioactive iodine-refractory differentiated thyroid cancer.

Sacks W, Braunstein GD.

Endocr Pract. 2014 Mar;20(3):263-75. doi: 10.4158/EP13305.RA. Review.

PMID:
24126232
18.
19.

Targeted therapy for gastric cancer--current status.

Kulig J, Kołodziejczyk P, Kulig P, Legutko J.

J Oncol Pharm Pract. 2013 Mar;19(1):75-81. doi: 10.1177/1078155212449030. Epub 2012 Jun 18. Review.

PMID:
22711713
20.

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ.

Drug Des Devel Ther. 2016 Feb 29;10:873-84. doi: 10.2147/DDDT.S93459. eCollection 2016. Review.

Supplemental Content

Support Center